ADC Name	Ab4-AM2 D265C.LALA.H435A
Synonyms	Ab4-AM2 D265C.LALA.H435A    Click to Show/Hide
Organization	Vor Biopharma Inec.
Drug Status	Investigative
Drug-to-Antibody Ratio	1.6
Antibody Name	Undisclosed
Antigen Name	Receptor-type tyrosine-protein phosphatase C (PTPRC)					Antigen Info
Payload Name	Undisclosed
Linker Name	Undisclosed

Standard Type	Value	Units	Description	Reference
Area Under the Concentration-Time Curve (AUC)	136	ug/mL/mg	The overlay of the anti-amatoxin detection-based PK with the anti-IgG detection-based PK indicated the ADC was serum stable.	[1]
Maximum Observed Concentration (Cmax)	14.7	ug/mL/mg	The overlay of the anti-amatoxin detection-based PK with the anti-IgG detection-based PK indicated the ADC was serum stable.	[1]
Time to Maximum Concentration (Tmax)	0.083	hr	The overlay of the anti-amatoxin detection-based PK with the anti-IgG detection-based PK indicated the ADC was serum stable.	[1]

Standard Type	Value	Units	Description	Reference
Volume of Distribution (Vd)	81.8	mL/kg	The overlay of the anti-amatoxin detection-based PK with the anti-IgG detection-based PK indicated the ADC was serum stable.	[1]

Standard Type	Value	Units	Description	Reference
Elimination Half-Life (t1/2)	7.4	hr	The overlay of the anti-amatoxin detection-based PK with the anti-IgG detection-based PK indicated the ADC was serum stable.	[1]
Clearance (CL)	7.35	mL/hr/kg	The overlay of the anti-amatoxin detection-based PK with the anti-IgG detection-based PK indicated the ADC was serum stable.	[1]

Standard Type	Value	Units	Cell Line	Disease Model
Half Maximal inhibitory Concentration (IC50)	0.025	nM	CVCL_0140	Normal
Half Maximal inhibitory Concentration (IC50)	0.066	nM	CVCL_1650	B lymphoblastic leukemia/lymphoma with t(12, B-lymphoblastic leukemia/lymphoma with t(12, Childhood B acute lymphoblastic leukemia
Half Maximal inhibitory Concentration (IC50)	0.066	nM	CVCL_1650	B lymphoblastic leukemia/lymphoma with t(12, B-lymphoblastic leukemia/lymphoma with t(12, Childhood B acute lymphoblastic leukemia
Half Maximal inhibitory Concentration (IC50)	0.2378	nM	CVCL_2196	Adult acute myeloid leukemia
Half Maximal inhibitory Concentration (IC50)	0.38	nM	CVCL_0065	T acute lymphoblastic leukemia

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.025 nM	Positive CD45,Ab4 expression (CD45,Ab4 +++/++)
Method Description	In vitro cell line killing assay - IC50 values
In Vitro Model	Normal	PBMC cells		CVCL_0140
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.066 nM	Positive CD45,Ab4 expression (CD45,Ab4 +++/++)
Method Description	In vitro Jurkat, REH, and SKNO-1 cell line killing assay - IC50 values
In Vitro Model	B lymphoblastic leukemia/lymphoma with t(12, B-lymphoblastic leukemia/lymphoma with t(12, Childhood B acute lymphoblastic leukemia	REH cells (CD45+)		CVCL_1650
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.066 nM	Negative CD45 expression (CD45-)
Method Description	In vitro REH cell line killing assay - IC50 values
In Vitro Model	B lymphoblastic leukemia/lymphoma with t(12, B-lymphoblastic leukemia/lymphoma with t(12, Childhood B acute lymphoblastic leukemia	REH cells (CD45-)		CVCL_1650
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.2378 nM	Positive CD45,Ab4 expression (CD45,Ab4 +++/++)
Method Description	In vitro Jurkat, REH, and SKNO-1 cell line killing assay - IC50 values
In Vitro Model	Adult acute myeloid leukemia	SKNO-1 cells		CVCL_2196
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)	0.38 nM	Positive CD45,Ab5 expression (CD45,Ab5 +++/++)
Method Description	In vitro Jurkat, REH, and SKNO-1 cell line killing assay - IC50 values
In Vitro Model	T acute lymphoblastic leukemia	Jurkat cells		CVCL_0065

Ref 1	Anti-CD45 antibodies and conjugates thereof